Skip to main content
Premium Trial:

Request an Annual Quote

Quanterix Gets Investment from In-Q-Tel

NEW YORK (GenomeWeb News) – Quanterix today said that it has received an investment from In-Q-Tel, an independent strategic investment firm that identifies technologies that support the missions of the US intelligence community, to support further development of its Single Molecule Array (SiMoA) technology.

Cambridge, Mass.-based Quanterix said that it would work with In-Q-Tel to develop its platform to enable simultaneous measurement of both nucleic acids and proteins for the detection of pathogens. It said that SiMoA will "facilitate the direct and non-amplified detection of pathogens to obtain a level of sensitivity that could previously only be achieved with amplification methods."

Quanterix did not disclose the amount of the investment by In-Q-Tel.

"The ability to accurately detect the presence of low abundance molecules makes Quanterix technology a critical addition to our strategic investment portfolio," Syd Ulvick, VP of physical and biological technologies practice at In-Q-Tel, said in a statement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.